Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Dendritic Cell Cancer Vaccine Market size was over USD 730.17 million in 2024 and is poised to exceed USD 3.22 billion by 2037, witnessing over 12.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of dendritic cell cancer vaccine is evaluated at USD 805.27 million.
Concerning the increased awareness among people about therapies and their side effects, the market is anticipated to experience a boost, as a result of minimal side effects that it has on the patients. The increasing number of chronic disease sufferers and technological advancement is further estimated to result in an upward slope in the growth chart.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of dendritic cell cancer vaccine is evaluated at USD 805.27 million.
Dendritic Cell Cancer Vaccine Market size was over USD 730.17 million in 2024 and is poised to exceed USD 3.22 billion by 2037, witnessing over 12.1% CAGR during the forecast period i.e., between 2025-2037.
North America industry is predicted to account for largest revenue share by 2037, as people in the region are more aware and the diagnosis techniques are supreme in these areas.
The major players in the market are Kite Pharma, Argos Therapeutics, Dendreon, GlaxoSmithKline, Batavia Biosciences, ImmunoCellular Therapeutics Ltd., Elios Therapeutics, Merck & Co., Tella Incorporation, and others.
